Guidance
← 실적 발표
01
02
03
04 05 06
톤
AI
A1 A2 A3
KVUE
FY2025 Q2
하향
Kenvue Inc. 실적 발표
Buzzberg 분석
Revised 2025 guidance to low single-digit organic sales decline
Kenvue's Q2 2025 call was dominated by a significant miss on top-line results and a substantial revision down of full-year guidance, reflecting severe operational and execution challenges. New interim CEO Kirk Perry emphasized reducing self-induced complexity and focusing on key brands, while CFO Amit Banati highlighted inventory destocking and weak seasonal dynamics as primary drivers of the poor performance. The tone was defensive and markedly negative, with management admitting execution failures and a lack of consistency. Guided 2025 organic sales down low single digits, a significant deterioration, and FY2025 EPS to $1.00-$1.05.
Buzzberg 분석 Revised 2025 guidance to low single-digit organic sales decline Kenvue's Q2 2025 call was dominated by a significant miss on top-line results and a substantial revision down of full-year guidance, reflecting severe operational and execution challenges. New interim CEO Kirk Perry emphasized reducing self-induced complexity and focusing on key brands, while CFO Amit Banati highlighted inventory destocking and weak seasonal dynamics as primary drivers of the poor performance. The tone was defensive and markedly negative, with management admitting execution failures and a lack of consistency. Guided 2025 organic sales down low single digits, a significant deterioration, and FY2025 EPS to $1.00-$1.05. 전체 분석 보기분석 접기
Kenvue's Q2 2025 call was dominated by a significant miss on top-line results and a substantial revision down of full-year guidance, reflecting severe operational and execution challenges. New interim CEO Kirk Perry emphasized reducing self-induced complexity and focusing on key brands, while CFO Amit Banati highlighted inventory destocking and weak seasonal dynamics as primary drivers of the poor performance. The tone was defensive and markedly negative, with management admitting execution failures and a lack of consistency. Guided 2025 organic sales down low single digits, a significant deterioration, and FY2025 EPS to $1.00-$1.05.
- Reported Q2 2025 organic sales declined 4.2% year-over-year, massively underperforming consumption growth, driven by retailer inventory destocking.
- Identified a 83% of US self-care business held or gained share, with Tylenol and Zyrtec as bright spots despite weak seasons.
- Admitted to self-induced complexity with 115 brands and a long tail of SKUs accounting for ~1% of sales.
매출$3.839B+3% 전분기 대비
주당순이익(EPS)$0.29+21% 전분기 대비
매출총이익률58.9%보고값
영업이익률18.03%보고값
근거 있는 핵심 내용 6개
지금 중요한 점
이번 발표에서 가장 의미 있는 변화를 정리했습니다.
Strategy
Plan to reduce complexity by trimming SKU tail
Leadership
New leaders appointed to one-third of leadership team
핵심 내용 3개 더 보기
Strategy
Strategic review of alternatives underway with board committee
Costs
Tariffs expected to have $150 million annualized impact
Performance
Q2 organic sales declined 4.2%, below expectations
보고 기간
보고 실적
| 지표 | 보고값 | 변화 |
|---|---|---|
| 매출 | $3.839B | +3% 전분기 대비 |
| 주당순이익(EPS) | $0.29 | +21% 전분기 대비 |
| 매출총이익률 | 58.9% | 보고값 |
| 영업이익률 | 18.03% | 보고값 |
| 잉여현금흐름 | $0.533B | 보고값 |
| 자본지출 | $0.088B | 보고값 |
향후 전망
향후 가이던스
| 지표 | 기간 | 범위 | 중간값 | 상태 |
|---|---|---|---|---|
| 주당순이익(EPS) | FY2025 | $1.00–$1.05 | $1.02 | 하향 |
| 매출 | FY2025 | -3%–-1% | -2% | 하향 |
AI, 자본지출 및 수요 분석
경영진 분석
Cautiously Determine
Management acknowledged weak results and challenges, but expressed confidence in executing a turnaround through focused priorities and leadership changes.
경영진의 AI 분석
Management emphasized leveraging data and AI capabilities as part of a modern CPG playbook, and announced a new Chief Technology and Data Officer to accelerate digital and AI capabilities.
아래에 언급된 기업 5개 모두 표시
기업발표 이후 수익률
공급망
공급망
Amit Banati
Kenvue's massive underperformance versus consumption (4.2% sales decline vs. positive consumption) implies retailers are aggressively destocking, which will pressure their wholesale partners' near-term revenue visibility. — The consumption-to-shipment gap indicates a channel-wide inventory correction, which could signal a temporary headwind for competitors relying on shipments to retailers for their own reported sales.
근거
“global consumption grew year over year and outpaced organic sales across each segment.”
공급망
Kirk Perry
Despite a record-weak US allergy season, Zyrtec gained household penetration and share. This points to share gains coming from competitors, not category growth, putting pressure on rival allergy brands. — Zyrtec's share and penetration gains during a weak tide indicate it is taking share from competitors, signaling a negative trend for competing allergy franchises in the US.
근거
“Zyrtec didn't just strengthen its leadership position, but also grew household penetration across both adult and children franchises.”
공급망
Amit Banati
Kenvue explicitly stated it is losing share in mouthwash because it is not playing strongly enough in the fastest-growing mild alcohol-free segment, a direct signal to competitors with strong offerings in that segment. — This admission provides a clear roadmap for competitors to double down on the alcohol-free oral care segment to entrench their share gains against Listerine.
근거
“The key challenge our teams are addressing is on our portfolio mix where we are not playing strongly enough in the fastest growing mild alcohol free segment.”
외부 신호
공급망 알파 · 3발표 이후 수익률
Kenvue's massive underperformance versus consumption (4.2% sales decline vs. positive consumption) implies retailers are aggressively destocking, which will pressure their wholesale partners' near-term revenue visibility.
Despite a record-weak US allergy season, Zyrtec gained household penetration and share. This points to share gains coming from competitors, not category growth, putting pressure on rival allergy brands.
Kenvue explicitly stated it is losing share in mouthwash because it is not playing strongly enough in the fastest-growing mild alcohol-free segment, a direct signal to competitors with strong offerings in that segment.
방법론 및 범위
경영진 발언만 분석합니다. 검증된 기업 언급 5개를 모두 표시하며, 보고 실적과 향후 가이던스를 분리합니다. 공개 근거는 화자가 표시된 짧은 인용문 8개로 제한됩니다. AI 분석은 불완전하거나 틀릴 수 있으므로 중요한 주장은 원문에서 확인하세요.